Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Tufts University School of Medicine, Boston, MA 02111, USA; University of Buckingham, Buckingham MK18 1EG, UK.
Med. 2021 Dec 10;2(12):1292-1313. doi: 10.1016/j.medj.2021.11.001.
Detection of minimal residual disease in patients with cancer, who are in complete remission with no cancer cells detectable, has the potential to improve recurrence-free survival through treatment selection. Studies analyzing circulating tumor DNA (ctDNA) in patients with solid tumors suggest the potential to accurately predict and detect relapse, enabling treatment strategies that may improve clinical outcomes. Over the past decade, assays for ctDNA detection in plasma samples have steadily increased in sensitivity and specificity. These are applied for the detection of residual disease after treatment and for earlier detection of recurrence. Novel clinical trials are now assessing how assays for "residual disease and recurrence" (RDR) may influence current treatment paradigms and potentially change the landscape of risk classification for cancer recurrence. In this review, we appraise the progress of RDR detection using ctDNA and consider the emerging role of liquid biopsy in the monitoring and management of solid tumors.
在癌症患者完全缓解且无法检测到癌细胞的情况下，检测微小残留病有可能通过治疗选择改善无复发生存期。分析实体瘤患者循环肿瘤 DNA（ctDNA）的研究表明，有可能准确预测和检测复发，从而制定可能改善临床结果的治疗策略。在过去十年中，用于检测血浆样本中 ctDNA 的检测方法在灵敏度和特异性方面稳步提高。这些方法用于治疗后残留疾病的检测和更早地检测复发。新的临床试验现在正在评估“残留疾病和复发”（RDR）检测的检测方法如何影响当前的治疗模式，并可能改变癌症复发风险分类的格局。在这篇综述中，我们评估了使用 ctDNA 进行 RDR 检测的进展，并考虑了液体活检在实体瘤监测和管理中的新兴作用。
